Shares of Inventiva S.A. (NASDAQ:IVA – Get Free Report) shot up 2.3% on Wednesday . The stock traded as high as $2.33 and last traded at $2.20. 8,094 shares changed hands during trading, a decline of 67% from the average session volume of 24,509 shares. The stock had previously closed at $2.15.
Inventiva Stock Down 2.3 %
The business’s fifty day moving average is $2.78 and its 200 day moving average is $3.33.
Institutional Trading of Inventiva
A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new stake in shares of Inventiva S.A. (NASDAQ:IVA – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Articles
- Five stocks we like better than Inventiva
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- The Cannabis Sector: Profitability Takes Center Stage
- What is the Euro STOXX 50 Index?
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- What is a Secondary Public Offering? What Investors Need to Know
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
